Suppr超能文献

基于基因和细胞疗法的炎症性肠病治疗策略。

Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

作者信息

van der Marel Sander, Majowicz Anna, van Deventer Sander, Petry Harald, Hommes Daniel W, Ferreira Valerie

机构信息

Department of Research and Development, Amsterdam Molecular Therapeutics BV, 1105 BA Amsterdam, The Netherlands.

出版信息

World J Gastrointest Pathophysiol. 2011 Dec 15;2(6):114-22. doi: 10.4291/wjgp.v2.i6.114.

Abstract

Inflammatory bowel diseases (IBD) are a group of chronic inflammatory disorders most commonly affecting young adults. Currently available therapies can result in induction and maintenance of remission, but are not curative and have sometimes important side effects. Advances in basic research in IBD have provided new therapeutic opportunities to target the inflammatory process involved. Gene and cell therapy approaches are suitable to prevent inflammation in the gastrointestinal tract and show therefore potential in the treatment of IBD. In this review, we present the current progress in the field of both gene and cell therapy and future prospects in the context of IBD. Regarding gene therapy, we focus on viral vectors and their applications in preclinical models. The focus for cell therapy is on regulatory T lymphocytes and mesenchymal stromal cells, their potential for the treatment of IBD and the progress made in both preclinical models and clinical trials.

摘要

炎症性肠病(IBD)是一组最常影响年轻人的慢性炎症性疾病。目前可用的疗法可诱导并维持缓解,但无法治愈,且有时会产生严重的副作用。IBD基础研究的进展为针对相关炎症过程提供了新的治疗机会。基因和细胞疗法适用于预防胃肠道炎症,因此在IBD治疗中显示出潜力。在本综述中,我们介绍了基因和细胞疗法领域的当前进展以及IBD背景下的未来前景。关于基因疗法,我们重点关注病毒载体及其在临床前模型中的应用。细胞疗法的重点是调节性T淋巴细胞和间充质基质细胞、它们在IBD治疗中的潜力以及在临床前模型和临床试验中取得的进展。

相似文献

1
Gene and cell therapy based treatment strategies for inflammatory bowel diseases.
World J Gastrointest Pathophysiol. 2011 Dec 15;2(6):114-22. doi: 10.4291/wjgp.v2.i6.114.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
3
Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges.
J Inflamm Res. 2023 May 16;16:2089-2119. doi: 10.2147/JIR.S400447. eCollection 2023.
5
Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Curr Stem Cell Res Ther. 2017;12(8):644-657. doi: 10.2174/1574888X12666170914113633.
6
Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Hum Vaccin Immunother. 2018;14(11):2597-2611. doi: 10.1080/21645515.2018.1461297. Epub 2018 May 22.
7
Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
Aliment Pharmacol Ther. 2017 Jan;45(2):205-221. doi: 10.1111/apt.13864. Epub 2016 Nov 22.
9
Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Inflamm Bowel Dis. 2021 Nov 15;27(Suppl 2):S38-S62. doi: 10.1093/ibd/izab190.
10
Management of Inflammatory Bowel Disease Using Stem Cell Therapy.
Curr Stem Cell Res Ther. 2016;11(1):72-7. doi: 10.2174/1574888x10666150728121738.

引用本文的文献

1
Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review.
J Clin Med. 2025 Aug 29;14(17):6119. doi: 10.3390/jcm14176119.
2
Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery.
Theranostics. 2024 Jan 1;14(1):1-16. doi: 10.7150/thno.89913. eCollection 2024.
3
Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord.
Pharmaceutics. 2023 Apr 13;15(4):1230. doi: 10.3390/pharmaceutics15041230.
4
Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.
World J Stem Cells. 2020 Oct 26;12(10):1050-1066. doi: 10.4252/wjsc.v12.i10.1050.
5
Crohn's Disease: Potential Drugs for Modulation of Autophagy.
Medicina (Kaunas). 2019 May 29;55(6):224. doi: 10.3390/medicina55060224.
8
Serum matrix metalloproteinase 9 (MMP9) as a biochemical marker for wasting marmoset syndrome.
J Vet Med Sci. 2016 Jun 1;78(5):837-43. doi: 10.1292/jvms.15-0675. Epub 2016 Feb 12.
9
Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes.
Mol Pharm. 2015 Feb 2;12(2):621-9. doi: 10.1021/mp5006883. Epub 2015 Jan 15.
10
Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation.
J Pharmacol Exp Ther. 2015 Feb;352(2):315-24. doi: 10.1124/jpet.114.218750. Epub 2014 Dec 3.

本文引用的文献

1
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles.
Mol Ther. 2008 Jul;16(7):1252-1260. doi: 10.1038/mt.2008.100. Epub 2016 Dec 8.
3
Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.
Inflamm Bowel Dis. 2011 Sep;17(9):1936-42. doi: 10.1002/ibd.21579. Epub 2010 Dec 10.
4
A population-based study of fatigue and sleep difficulties in inflammatory bowel disease.
Inflamm Bowel Dis. 2011 Sep;17(9):1882-9. doi: 10.1002/ibd.21580. Epub 2010 Dec 22.
8
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?
J Immunother. 2011 May;34(4):336-42. doi: 10.1097/CJI.0b013e318217007c.
9
State-of-the-art gene-based therapies: the road ahead.
Nat Rev Genet. 2011 May;12(5):316-28. doi: 10.1038/nrg2971. Epub 2011 Apr 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验